ALS drug trial halted: what happened with BIIB105?
NCT ID NCT04494256
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental drug called BIIB105 in adults with ALS, a progressive nerve disease. The trial had two parts: a 6-month placebo-controlled phase and a 3-year open-label extension where everyone received the drug. The goal was to check safety, how the body processes the drug, and whether it could slow disease progression. However, the study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BIIB105
What this could lead to
If it works, this could point toward a treatment that slows the worsening of ALS symptoms.
What could go wrong
This early-stage trial was terminated, so results are limited. The drug is still experimental, and its safety and effectiveness are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O.U. Città della salute e della scienza di Torino
Torino, Italy
-
ALS Clinic - Department of Neurology, Neuromuscular Division, Johns Hopkins University, School of Medicine
Baltimore, Maryland, 21218, United States
-
Barrow Neurological Institute
Phoenix, Arizona, 85013, United States
-
Georgetown University
Washington D.C., District of Columbia, 20007-2113, United States
-
Houston Methodist Neurological Institute
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Montreal Neurological Institute-Hospital
Montreal, Quebec, H3A 2B4, Canada
-
Orlando Health
Orlando, Florida, 32806, United States
-
Stanford Neuromuscular Research Center
Palo Alto, California, 94305, United States
-
The Emory Clinic
Atlanta, Georgia, 30322, United States
-
UMC Utrecht
Utrecht, 3584 CX, Netherlands
-
University of California San Diego Medical Center
La Jolla, California, 92037, United States
-
University of Colorado Hospital - Neuroscience Center -Anschutz Medical Campus
Aurora, Colorado, 80045, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Utah
Salt Lake City, Utah, 84132, United States
-
Washington University, School of Medicine
St Louis, Missouri, 63110, United States